Combined, targeted hypermethylation of either the KLF5 mRNA or miR-29a might prove therapeutic in conditions where VSMC hyperproliferation holds a central pathophysiologic role, including atherosclerosis, arterial aneurysms, and both pulmonary and systemic hypertension. Here, KLF5 is linked to atherosclerosis.